Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Soledad Retamozo, Antoni Sisó-Almirall, Alejandra Flores-Chávez, Manuel Ramos-Casals & Pilar Brito-Zerón. (2021) An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. Expert Opinion on Pharmacotherapy 22:17, pages 2359-2371.
Read now
Read now
Articles from other publishers (15)
Lu Shi, Jinyu Hu, Hualu Wu, Yuxin Shen, Xiaohai Chen, Qinghua Weng, Ren-ai Xu & Congrong Tang. (2024) Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction. Journal of Pharmaceutical and Biomedical Analysis 243, pages 116079.
Crossref
Crossref
Yann Nguyen, Maxime Beydon, Nathan Foulquier, Rachael Gordon, Coralie Bouillot, Katherine M Hammitt, Simon J Bowman, Xavier Mariette, Sara S McCoy, Divi Cornec & Raphaèle Seror. (2024) Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group. Seminars in Arthritis and Rheumatism 65, pages 152385.
Crossref
Crossref
Nadine Zehrfeld, Torsten Witte & Diana Ernst. (2024) Update zum Sjögren-Syndrom: Diagnostik & Therapie. Aktuelle Rheumatologie.
Crossref
Crossref
Xuan Cai, Ruo‐Yun Gui, Jin Wu, Chen‐Cong Wang, Xiao‐Lu Zhu, Hai‐Xia Fu & Xiao‐Hui Zhang. (2024) Decreased Expression of IL‐35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia. Advanced Science 11:12.
Crossref
Crossref
Liuting Zeng, Qi He, Ying Deng, Yuwei Li, Junpeng Chen, Kailin Yang, Yanfang Luo, Anqi Ge, Xiaofei Zhu, Zhiyong Long & Lingyun Sun. (2023) Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials. Frontiers in Pharmacology 14.
Crossref
Crossref
Shuying Wang, Jiake Yu, Jie Yang, Yan Ge & Jing Tian. (2023) Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice. Scientific Reports 13:1.
Crossref
Crossref
Taibiao Lyu, Hui Jiang, Liuting Zeng, Suying Liu, Chengmei He, Chaowen Luo, Lin Qiao, Yan Zhao & Hua Chen. (2023) Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling. Arthritis Research & Therapy 25:1.
Crossref
Crossref
Xiaoyan Wang, Xiang Lin, Yingying Su & Hao Wang. (2023) Systematic review with meta-analysis: Efficacy and safety of biological treatment on salivary gland function in primary Sjögren’s syndrome. Frontiers in Pharmacology 14.
Crossref
Crossref
Jacob Ritter, Yidan Chen, Ana-Luisa Stefanski & Thomas Dörner. (2022) Current and future treatment in primary Sjögren's syndrome – A still challenging development. Joint Bone Spine 89:6, pages 105406.
Crossref
Crossref
Jacob Ritter, Yidan Chen, Ana-Luisa Stefanski & Thomas Dörner. (2022) Traitements actuels et futurs du Syndrome de Sjögren primitif – un développement ambitieux. Revue du Rhumatisme 89:5, pages 465-473.
Crossref
Crossref
Zhen Tan, Li Wang & Xiaomei Li. (2022) Composition and regulation of the immune microenvironment of salivary gland in Sjögren’s syndrome. Frontiers in Immunology 13.
Crossref
Crossref
Liuting Zeng, Qi He, Kailin Yang, Wensa Hao, Ganpeng Yu & Hua Chen. (2022) A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome. Frontiers in Immunology 13.
Crossref
Crossref
Jun Tao, Li Sun, Zijie Wang, Hao Chen, Zhijian Han, Hengcheng Zhang, Haiwei Yang, Zhengkai Huang, Shuang Fei, Xiaobin Ju, Ruoyun Tan & Min Gu. (2021) Efficacy and Safety of Iguratimod Supplement to the Standard Immunosuppressive Regimen in Highly Mismatched Renal Transplant Recipients: A Pilot Study. Frontiers in Immunology 12.
Crossref
Crossref
Jincheng Pu, Xuan Wang, Farooq Riaz, Tongyangzi Zhang, Ronglin Gao, Shengnan Pan, Zhenzhen Wu, Yuanyuan Liang, Shuqi Zhuang & Jianping Tang. (2021) Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Joyce J.B.C. van Beers & Jan G.M.C. Damoiseaux. (2021) Immune Monitoring upon Treatment with Biologics in Sjögren’s Syndrome: The What, Where, When, and How. Biomolecules 11:1, pages 116.
Crossref
Crossref